Table of Contents
Selected Publications
Complete Bibliography
Research Articles
Dorer DE, Holtrup F, Fellenberg K, Kaufmann JK, Engelhardt S, Hoheisel JD, Nettelbeck DM.
Replication and virus-induced transcriptome of HAdV-5 in normal host cells versus cancer cells--differences of relevance for adenoviral oncolysis.
PlosOne. Nov;6(11):e27934.
Quirin C, Rohmer S, Fernández-Ulibarri I, Behr M, Hesse A, Engelhardt S, Erbs P, Enk AH, Nettelbeck DM.
Selectivity and efficiency of late transgene expression by transcriptionally targeted oncolytic adenoviruses are dependent on the transgene insertion strategy.
Hum Gene Ther. 2011, Apr;22(4):389-404.
Krasny L, Shimony N, Tzukert K, Gorodetsky R, Lecht S, Nettelbeck DM, Haviv YS.
An in-vitro tumour microenvironment model using adhesion to type I collagen reveals Akt-dependent radiation resistance in renal cancer cells.
Nephrol Dial Transplant. 2010, Feb;25(2):373-80.
Rohmer S, Quirin C, Hesse A, Sandmann S, Bayer W, Herold-Mende C, Haviv YS, Wildner O, Enk AH, Nettelbeck DM
Transgene expression by oncolytic adenoviruses is modulated by E1B19K deletion in a cell type-dependent manner.
Virology. 2010, Dec 20;395(2):243-54.
Tzukert K, Shimony N, Krasny L, Urieli-Shoval S, Gorodetsky R, Avrahami I, Nettelbeck DM, Haviv YS.
Human melanoma cells expressing the alphavbeta3 integrin are partially protected from necrotic cell death induced by dynamic matrix detachment.
Cancer Lett. 2009, Oct 3.
Knippertz I, Hesse A, Schunder T, Kämpgen E, Brenner MK, Schuler G, Steinkasserer A, Nettelbeck DM.
Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma.
J Immunother. 2009, Jun;32(5):524-38.
Rohmer S, Mainka A, Knippertz I, Hesse A, Nettelbeck DM.
Insulated hsp70B' promoter: stringent heat-inducible activity in replication-deficient, but not replication-competent adenoviruses.
Gene Med. 2008, Apr;10(4):340-54.
Johnson TS, Mahnke K, Storn V, Schönfeld K, Ring S, Nettelbeck DM, Haisma HJ, Le Gall F, Kontermann RE, Enk AH.
Inhibition of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-205 single-chain fragment variable molecule.
Clin Cancer Res. 2008, Dec 15;14(24):8169-77.
Tzukert K, Gorodestky R, Avrahami I, Krasny L, Shimony N, Elkin G, Nettelbeck DM, Haviv YS.
A novel dynamic matrix detachment model reveals a shift from apoptosis to necrosis in melanoma cells.
Cancer Lett. 2008, Dec 18;272(2):345-54.
Schwenkert M, Birkholz K, Schwemmlein M, Kellner C, Kügler M, Peipp M, Nettelbeck DM, Schuler-Thurner B, Schaft N, Dörrie J, Ferrone S, Kämpgen E, Fey GH.
A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells.
Melanoma Res. 2008, Apr;18(2):73-84.
Schierer S, Hesse A, Müller I, Kämpgen E, Curiel DT, Schuler G, Steinkasserer A, Nettelbeck DM.
Modulation of viability and maturation of human monocyte-derived dendritic cells by oncolytic adenoviruses.
Int J Cancer. 2008, Jan 1;122(1):219-29.
Hoffmann D, Bayer W, Heim A, Potthoff A, Nettelbeck DM, Wildner O.
Evaluation of Twenty-One Human Adenovirus Types and One Infectivity-Enhanced Adenovirus for the Treatment of Malignant Melanoma.
J Invest Dermatol. 2007, Oct 25;
Ulasov IV, Rivera AA, Nettelbeck DM, Rivera LB, Mathis JM, Sonabend AM, Tyler M, Wang M, Douglas JT, Lesniak MS.
An oncolytic adenoviral vector carrying the tyrosinase promoter for glioma gene therapy.
Int J Oncol. 2007, Nov;31(5):1177-85.
Quirin C, Mainka A, Hesse A, Nettelbeck DM.
Combining adenoviral oncolysis with temozolomide improves cell killing of melanoma cells.
Int J Cancer. 2007, Dec 15;121(12):2801-7.
Hesse A, Kosmides D, Kontermann RE, Nettelbeck DM.
Tropism modification of adenovirus vectors by peptide ligand insertion into various positions of the adenovirus serotype 41 short-fiber knob domain.
J Virol. 2007, 81(6):2688-99.
Hoffmann D, Heim A, Nettelbeck DM, Steinstraesser L, Wildner O.
Evaluation of twenty human adenoviral types and one infectivity-enhanced adenovirus for the therapy of soft tissue sarcoma.
Hum Gene Ther. 2007, 18(1):51-62
Bauerschmitz G.J., Guse K., Kanerva A., Menzel A., Herrmann I., Desmond R.A., Yamamoto M., Nettelbeck D.M., Hakkarainen T., Dall P., Curiel D.T. und Hemminki A.
Triple-Targeted Oncolytic Adenoviruses Featuring the Cox2 Promoter, E1A Transcomplemen-tation, and Serotype Chimerism for Enhanced Selectivity for Ovarian Cancer Cells.
Molecular Therapy. 2006, 14(2):164-174
Rein D.T., Breidenbach M., Kirby T.O., Han T., Siegal G.P., Bauerschmitz G.J., Wang M., Nettelbeck D.M., Tsuruta Y., Yamamoto M., Dall P., Hemminki A. und Curiel D.T.
A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
Clin Cancer Res. 2005, 11(3), 1327-1335
Lu B., Makhija S.K., Nettelbeck D.M., Rivera A.A., Wang M., Komarova S., Zhou F., Yamaoto M., Haisma, H.J., Alvarez R.D., Curiel D.T. und Zhu Z.B.
Evaluation of tumor specific promoter activities in melanoma.
Gene Therapy. 2005, 12(4), 330-338
Rein D.T., Breidenbach M., Nettelbeck D.M., Kawakami Y., Siegal G.P., Huh W.K., Wang M., Hemminki A., Bauerschmitz G.J., Yamamoto M., Adachi Y., Takayama K., Dall P. und Curiel D.T.
Evaluation of tissue-specific promoters in carcinomas of the cervix uteri.
J Gene Med. 2004, 6, 1281-1289.
Rivera A.A., Davydova J., Schierer S., Wang M., Krasnykh V., Yamamoto M., Curiel D.T. und Nettelbeck D.M.
Combining High Selectivity of Replication with Fiber Chimerism for Effective Adenoviral Oncolysis of CAR-Negative Melanoma Cells.
Gene Therapy. 2004, 11, 1694-1702.
Banerjee N.S., Rivera A.A., Wang M., Chow L.T., Broker T.R., Curiel D.T. und Nettelbeck D.M.
Development of Melanoma-Targeted Oncolytic Adenoviruses with Tyrosinase Enhancer/ Promoter Driving Expression of E1A and E4 and their Analysis in Organotypic Raft Cultures.
Molecular Cancer Therapeutics. 2004, 3(4), 437-449
Korn T., Nettelbeck D.M., Völkel T., Müller R. und Kontermann R.E.
Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: A comparative analysis of bacterially expressed single-chain diabody and tandem scFv.
J Gene Med. 2004, 6(6), 642-651.
Zhu Z.B., Makhija S.K., Lu B., Wang M., Kaliberova L., Liu B., Rivera A.A., Nettelbeck D.M., Mahasreshti P.J., Leath, III C.A., Yamaoto M., Alvarez R.D. und Curiel, D.T.
Transcriptional targeting of adenoviral vector through the CXCR4 tumor specific promoter.
Gene Therapy. 2004, 11(7), 645-648
Rivera A.A., Wang M., Suzuki K., Uil T.G., Krasnykh V., Curiel D.T., und Nettelbeck D.M.
Mode of Transgene Expression after Fusion to Early or Late Viral Genes of a Conditionally Replicating Adenovirus via an Optimized Internal Ribosome Entry Site in vitro and in vivo
Virology. 2004, 320/1, 121-134
Nettelbeck D.M., Rivera A.A., Kupsch J., Dieckmann D., Douglas J.T., Kontermann R.E., Alemany R., und Curiel D.T.
Retargeting of Adenoviral Infection to Melanoma: Combining Genetic Ablation of Native Tropism with a Recombinant Bispecific Single-Chain Diabody (scDb) Adapter that Binds to Fiber Knob and HMWMAA.
Int J Cancer. 2004, 108, 136-145
Volk A.L., Rivera A.A., Kanerva A., Bauerschmitz G., Dmitriev I., Krasnykh V., Nettelbeck D.M. und Curiel D.T.
Enhanced Adenovirus Infection of Melanoma Cells by Fiber-Modification: Incorporation of RGD Peptide or Ad5/3 Chimerism
Cancer Biology and Therapy. 2003, 2(5), 511-515.
Barker S.D., Dmitriev I.P., Nettelbeck D.M., Lui B., Rivera A.A., Alvarez R.D., Curiel D.T. und Hemminki A.
Combined transcriptional and trasductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma.
Gene Therapy. 2003, 10, 1198-1204
Nettelbeck D.M., Rivera A.A., Davydova J., Dieckmann, D., Yamamoto M. und Curiel D.T.
Cox-2 Promoter for Tumor-Specific Targeting of Adenoviral Vectors to Melanoma.
Melanoma Research. 2003, 13, 287-292
Takikawa H., Mafune K., Hamada H., Nettelbeck D.M., Muller R., Makuuchi M. und Kaminishi M.
An advanced strategy of enhanced specific gene expression for hepatocellular carcinoma.
Int J Oncol. 2003, 22(5), 1051-1056
Nettelbeck D.M., Rivera A.A., Balague C., Alemany R. und Curiel D.T.
Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter.
Cancer Research. 2002, 62, 4663 - 4670
Bauerschmitz G.J., Lam J.T., Kanerva A., Suzuki K., Nettelbeck D.M., Dmitriev I., Krasnykh V., Mikheeva G.V., Barnes M.N., Alvarez R.D., Alemany R., Curiel D.T. und Hemminki A.
A Tropism Modified Oncolytic Adenovirus for Treatment of Ovarian Cancer.
Cancer Research. 2002, 62, 1266 - 1270
Bauerschmitz G.J., Nettelbeck D.M., Kanerva A., Baker A.H., Hemminki A., Reynolds P.N. und Curiel D.T.
The flt-1 promoter for transcriptional targeting of teratocarcinoma.
Cancer Research, 2002, 62, 1271 - 1274
Arafat W.O., Gómez-Navarro J., Buchsbaum D.J., Xiang J., Wang M., Casado E., Barker S.D., Mahasreshti P.J., Haisma H.J., Barnes M.N., Siegal G.P., Alvarez R.D., Hemminki A., Nettelbeck D.M. und Curiel D.T.
Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv.
Gene Therapy. 2002, 9, 256 - 262
Nettelbeck D.M., Miller D.W., Jérôme V., Zuzarte M.-L., Watkins S.J., Hawkins R.E., Müller R. und Kontermann R.E.
Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105).
Mol Ther. 2001, 3, 882 - 891
Mahasreshti P.J., Gomez-Navarro J., Kataram M., Wang M.H., Carey D., Siegal G.P., Barnes M.N., Nettelbeck D.M., Alvarez R.D., Hemminki A. und Curiel D.T.
Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carvinoma.
Clinical Cancer Res. 2001, 7, 2057-2066
Heidtmann H.-H., Nettelbeck D.M., Mingels A., Jäger R., Welker H.-G. und
Kontermann R.E.
Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen.
Br J Cancer. 1999, 81, 1269 - 1273
Nettelbeck D.M., Jérôme V. und Müller R.
A dual specificity promoter system combining cell cycle-regulated and tissue-specific transcriptional control.
Gene Therapy. 1999, 6, 1276 - 1281.
Graulich W., Nettelbeck D.M., Fischer D., Kissel T. und Müller R.
Cell type specificity of the human endoglin promoter.
Gene. 1999, 227, 55 - 62.
Nettelbeck D.M., Jérôme V., Liu N., Zwicker J., Lucibello F.C. und Müller R.
Cell cycle-regulated and dual-specificity promoters for the targeting of tumor and tumor endothelial cells.
Gene Therapy Mol Biol. 1998, 2, 457-461.
Nettelbeck D.M., Jérôme V. und Müller R.
A strategy for enhancing the transcriptional activity of weak cell type-specific promoters.
Gene Therapy. 1998, 5, 1656-1664.
Nettelbeck D.M., Zwicker J., Lucibello F.C., Gross C., Liu N., Brüsselbach S. und
Müller R.
Cell cycle regulated promoters for the targeting of tumor endothelium.
Adv Exp Med Biol. 1998, 451, 437-40
Brüsselbach S., Nettelbeck D.M., Sedlacek H.-H. und Müller R.
Cell cycle-independent induction of apoptosis by the anti-tumor drug Flavopiridol in
endothelial cells.
Int J Cancer. 1998, 77, 146-152.
Reviews
Dorer DE, Nettelbeck DM.
Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis.
Adv Drug Deliv Rev. 2009, Jul 2;61(7-8):554-71.
Nettelbeck D.M.
Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer.
J Mol Med. 2008, Apr;86(4):363-77.
Nettelbeck D.M. und Curiel D.T.
Mit Viren gegen Krebs.
Spektrum der Wissenschaften. 2004, July, 24-31
Nettelbeck D.M. und Curiel D.T.
Tumor-Busting Viruses. A new technique called virotherapy harnesses viruses, those banes of humankind, to stop another scourge – cancer.
Scientific American. 2003, 289 (4), 68 – 75
Nettelbeck D.M.
Virotherapeutics: Conditionally Replicative Adenoviruses (CRAds) for Viral Oncolysis.
Anti-Cancer Drugs. 2003, 14, 577-584
Nettelbeck D.M.
Gene Therapy: New Strategies for Malignant Melanoma.
Science & Medicine. 2002, 8, September/Oktober
Casado E., Nettelbeck D.M., Gomez-Navarro J., Hemminki A., Gonzalez Baron M.,
Siegal G.P., Barnes M.N., Alvarez R.D. und Curiel D.T.
Transcriptional targeting for ovarian cancer gene therapy: A review
Gynecol Oncol. 2001, 82(2), 229 – 237
Nettelbeck D.M., Jérôme V. und Müller R.
Gene Therapy. Designer Promoters for Tumor Targeting.
Trends in Genetics. 2000, 16, 174-181
Book Chapters
Schaft, N., Dörrie, J. und Nettelbeck, D.M. (2006).
Antigen Delivery - Nucleic Acid Transfer. In: Dendritic Cells (ed. M. Lutz, N. Romani und A. Steinkasserer). Wiley & Sons, Inc., New York, NY, USA.
Nettelbeck, D.M., Curiel, D.T. und Müller, R. (2002).
Promoter Optimization and Artificial Promoters for Transcriptional Targeting in Gene Therapy. In: Vector Targeting for Therapeutic Gene Delivery (ed. D.T. Curiel, and J.T. Douglas). Wiley & Sons, Inc., New York, NY, USA.
Nettelbeck, D.M. und Müller, R. (2001).
Targeting of viral vectors for cancer gene therapy.
In: Drug targeting technology: a critical analysis of physical, chemical and biological methods (ed. H. Schreier). Marcel Dekker, Inc., New York, NY, USA.
